Literature DB >> 17420990

Use of RNA interference to elucidate the effect of MYCN on cell cycle in neuroblastoma.

Chan-Wook Woo1, Fei Tan, Hope Cassano, Junghwa Lee, Kwang Chul Lee, Carol J Thiele.   

Abstract

BACKGROUND: MYCN amplification marks poor prognosis in neuroblastoma (NB) tumors. In evaluating the mechanisms by which retinoic acid (RA) or nerve growth factor (NGF) decrease cell number in MYCN amplified NB cells, we have identified a number of proteins whose expression either decreases (E2F, CDC2, CDK6, cyclin dependent kinase activity) or increases (p27) in association with a decrease in MYCN expression. However, it was still unclear which were MYCN dependent effects or not. PROCEDURE: This study aimed to determine which changes in cell cycle gene expression are modulated as a consequence of the decrease in MYCN. We silenced MYCN expression using siRNA targeted to the coding region of MYCN. Then, by using siRNA transient transfections, we analyzed the change of cell cycle related genes and cell cycle in MYCN amplified NB cell lines.
RESULTS: We demonstrate that expression of MYCN can be suppressed by almost 60% in MYCN amplified NB cell using siRNAs targeted to MYCN. Functionally, the decrease in MYCN leads to a decrease in cells in the S-phase of the cell cycle. Decreases in MYCN are associated with decreases in E2F1-2 and ID2 along with increases in p27 protein levels by post-transcriptional modification. Moreover, we find that a decrease in MYCN is accompanied by a decrease in cdk6 mRNA and protein expression.
CONCLUSIONS: These results show that E2F and ID2 expression is associated with MYCN regulation and that cdk6 is a possible new transcriptional target of MYCN. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17420990     DOI: 10.1002/pbc.21195

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  17 in total

1.  Dihydropyrimidinase-like protein 3 expression is negatively regulated by MYCN and associated with clinical outcome in neuroblastoma.

Authors:  Fei Tan; Reema Wahdan-Alaswad; Shuang Yan; Carol J Thiele; Zhijie Li
Journal:  Cancer Sci       Date:  2013-10-21       Impact factor: 6.716

2.  Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification.

Authors:  Linda J Valentijn; Jan Koster; Franciska Haneveld; Rachida Ait Aissa; Peter van Sluis; Marloes E C Broekmans; Jan J Molenaar; Johan van Nes; Rogier Versteeg
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-22       Impact factor: 11.205

Review 3.  The genomic landscape of retinoblastoma: a review.

Authors:  Brigitte L Thériault; Helen Dimaras; Brenda L Gallie; Timothy W Corson
Journal:  Clin Exp Ophthalmol       Date:  2013-05-22       Impact factor: 4.207

4.  Oncolytic adenovirus armed with shRNA targeting MYCN gene inhibits neuroblastoma cell proliferation and in vivo xenograft tumor growth.

Authors:  Yuan Li; Baofu Zhang; Hongwei Zhang; Xiaoyu Zhu; Dongchuan Feng; Deyong Zhang; Baobiao Zhuo; Liantao Li; Junnian Zheng
Journal:  J Cancer Res Clin Oncol       Date:  2013-02-27       Impact factor: 4.553

5.  Overexpression of MYCN promotes proliferation of non-small cell lung cancer.

Authors:  Kun Liu; Shuo Wang; Yifei Liu; Jun Gu; Shudong Gu; Zhen Xu; Rui Zhang; Zhiwen Wang; Huaci Ma; Yingying Chen; Lili Ji
Journal:  Tumour Biol       Date:  2016-07-23

6.  A functional screen identifies miR-34a as a candidate neuroblastoma tumor suppressor gene.

Authors:  Kristina A Cole; Edward F Attiyeh; Yael P Mosse; Michael J Laquaglia; Sharon J Diskin; Garrett M Brodeur; John M Maris
Journal:  Mol Cancer Res       Date:  2008-05       Impact factor: 5.852

7.  The MYCN oncogene is a direct target of miR-34a.

Authors:  J S Wei; Y K Song; S Durinck; Q-R Chen; A T C Cheuk; P Tsang; Q Zhang; C J Thiele; A Slack; J Shohet; J Khan
Journal:  Oncogene       Date:  2008-05-26       Impact factor: 9.867

Review 8.  MYCN, neuroblastoma and focal adhesion kinase (FAK).

Authors:  Elizabeth A Beierle
Journal:  Front Biosci (Elite Ed)       Date:  2011-01-01

9.  Addiction of MYCN amplified tumours to B-MYB underscores a reciprocal regulatory loop.

Authors:  Francesco Gualdrini; Daisy Corvetta; Sandra Cantilena; Olesya Chayka; Barbara Tanno; Giuseppe Raschellà; Arturo Sala
Journal:  Oncotarget       Date:  2010-08

10.  p53, SKP2, and DKK3 as MYCN Target Genes and Their Potential Therapeutic Significance.

Authors:  Lindi Chen; Deborah A Tweddle
Journal:  Front Oncol       Date:  2012-11-28       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.